Viridos develops and commercializes genomic-driven solutions to address global energy and environmental challenges. It builds a platform for low-carbon-intensity biofuels that can reduce greenhouse gas emissions from aviation, commercial trucking, and maritime shipping. The company was formerly known as Synthetic Genomics. It was founded in 2005 and is based in La Jolla, California.
Research containing Viridos
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Viridos in 1 CB Insights research brief, most recently on Aug 31, 2021.
Expert Collections containing Viridos
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Viridos is included in 3 Expert Collections, including Synthetic Biology.
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Companies in the Renewable Energy space, including solar, wind, hydro, geothermal, and nuclear energy providers, as well as related software developers.
Oil & Gas Tech
Companies in the Oil & Gas Tech space, including those focused on improving operations across upstream, midstream, and downstream sectors, as well as those working on sustainable fuels.
Viridos has filed 140 patents.
Photosynthesis, Photosynthetic pigments, Aquatic ecology, Plant physiology, Microbiology
Photosynthesis, Photosynthetic pigments, Aquatic ecology, Plant physiology, Microbiology
Latest Viridos News
Nov 2, 2023
Directors with Key Appointments to Accelerate Synthetic Genomics to Innovate Biologic Therapies Industry veteran Dr Paul Wallace appointed as Chief Business Officer bringing 25 years of international business development experience commercialising innovative platforms and therapeutics Boston, MA-based serial entrepreneur and synthetic biology pioneer Rahul K Dhanda joins the Board of Directors as Non-Executive Director Constructive Bio continues rapid team expansion and moves to state-of-the-art South Cambridge facility Cambridge, United Kingdom – 2nd November 2023 – Constructive Bio (“the Company”), a biotech that rewrites genomes to create biomolecules that were previously unimaginable, announces the appointment of Dr Paul Wallace as Chief Business Officer (CBO), and Rahul K Dhanda as a Non-Executive Director (NED) with immediate effect. Dr Paul Wallace has been leading business development activities in both private and public companies for over 25 years. He has executed some of the industry’s most impactful strategic transactions with major pharma, regularly at the leading edge of deal trends. His proven track record of success includes out-licensing the hepatitis C protease inhibitor Olysio®, one of the fastest-launched drugs in the history of the industry. Paul joins Constructive Bio to accelerate the commercialisation and strategic partnering of its ground-breaking genetic code reprogramming platform. Prior to joining Constructive Bio, Paul was Chief Business Officer at Mission Therapeutics and Executive Vice President at Medivir where he helped guide company growth from a research-focused model to a profitable, commercial company with significant revenue. Paul had an earlier career in pharmaceutical research and carried out his PhD and post-doctoral studies in biochemistry at the University of Cambridge. He currently serves as the non-executive chairman of Semarion, a spin-out from the Cavendish Laboratory, University of Cambridge. Rahul K Dhanda, CEO and Director of Syntis Bio, which he co-founded with Professors Robert Langer and Giovanni Traverso, joins the Board with a successful background building platform companies based upon CRISPR, synthetic biology, imaging and more. He is the founding CEO of Sherlock Biosciences, where he led the launch of the first-ever CRISPR product to be authorized by the FDA, as well as Chair and co-founder of BLASTID, Inc. His diverse expertise in platform development, strategic partnering, commercialisation, and company-building supports the Company’s growing team. Ola Wlodek, Chief Executive Officer of Constructive Bio, commented, "Paul and Rahul bring a wealth of experience in partnering, developing and commercialising engineering biology solutions. They are perfect complements to our team developing Constructive Bio’s commercial-grade genetic code reprogramming platform. Through genome rewriting and advanced protein translation engineering, we are building programmable biomolecules that were previously unimaginable. “Their addition marks a significant stride in our ambitious journey towards innovating global therapeutic solutions and is perfectly timed as we expand into our new, custom-designed facility in South Cambridge.” Rahul Dhanda, NED of the Board of Directors of Constructive Bio, added: “It is an honour to join the Constructive Bio team, and I am excited to work with Dr Wlodek, Professor Chin, the Company’s investors, and most of all the incredible team that continues to revolutionise synthetic genomics. The synthetic genome platform at Constructive Bio is a powerful tool that will change the way we imagine biology, including the breakthrough therapies we need to improve global health.“ -ENDS-
Viridos Frequently Asked Questions (FAQ)
When was Viridos founded?
Viridos was founded in 2005.
Where is Viridos's headquarters?
Viridos's headquarters is located at 11149 North Torrey Pines Road, La Jolla.
What is Viridos's latest funding round?
Viridos's latest funding round is Series A.
How much did Viridos raise?
Viridos raised a total of $100.18M.
Who are the investors of Viridos?
Investors of Viridos include United Airlines Ventures, Chevron Technology Ventures, Breakthrough Energy Ventures, California Governor's Office of Business and Economic Development, Lung Biotechnology and 12 more.
Who are Viridos's competitors?
Competitors of Viridos include Performance Plants, greenlight, Lynntech, Amyris, Evolutionary Genomics and 7 more.
Compare Viridos to Competitors
Tethys Research is a discovery company focused on the biotechnology sector. The company's main services include the discovery of new enzymes and chemical entities, using its unique combination of expertise in various disciplines to tackle problems that cannot be addressed with high-throughput screening methodologies. Tethys primarily serves the chemical products and processes industry. It is based in Bangor, Maine.
ZeroPoint Clean Technology is a company focused on renewable energy, specifically in the biomass power plant sector. The company's main service involves the construction of 2-12MW biomass power plants using leading biomass gasification technology, which converts woody biomass into high-quality synthesis gas and a stable form of sequestered carbon, known as biochar. This synthesis gas can replace oil or gas in engines, burners, and boilers, or be used to produce chemicals and liquid fuels. It was founded in 2006 and is based in Potsdam, New York.
Freepower develops small scale turbine technology.
American Biodiesel, dba Community Fuels, is an advanced biofuel producer. The company produces among the highest quality biomass-based diesel fuels available - which qualifies as an Advanced Biofuel through the Environmental Protection Agency (EPA), and its own fuel standard closely mirrors the requirements of multiple major oil companies and exceeds the Federal fuel standard (ASTM Standard).
EnerTech Environmental is a renewable energy company operating in the environmental protection and waste management sectors. The company's main services include the development and commercialization of clean combustion technologies for biosolids and other organic wastes, which are converted into high-grade renewable fuel. EnerTech primarily serves the renewable energy industry. It was founded in 1992 and is based in Wichita, Kansas.
ThermoChem Recovery International markets a gasification technology that aims to transform the pulp and paper industry into biorefineries which will not only produce paper, but also renewable energy in the form of green electric power and bio-based fuels and chemicals. TRI's gasification process converts cellulosic feedstocks (including wood chips, bark, forest residuals, agricultural waste and energy crops) into a synthesis gas ("syngas") which can be used to replace natural gas and fuel oil, and can be converted into biofuels and biochemicals. Additionally, per the company, TRI's technology is capable of recovering energy and chemicals from spent pulping liquors. TRI licenses its gasification technology, and aims to provide specialized equipment and engineering services to pulp and paper companies seeking to integrate TRI's process into their mill operations. TRI's proven technology currently is in commercial use at two mills in the U.S. and Canada.